Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

Related Articles by Review for PubMed (Select 9499455)

1.
2.

Evolving role of uPA/uPAR system in human cancers.

Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH.

Cancer Treat Rev. 2008 Apr;34(2):122-36. Epub 2007 Dec 26. Review.

PMID:
18162327
3.

Targeting uPA/uPAR in prostate cancer.

Li Y, Cozzi PJ.

Cancer Treat Rev. 2007 Oct;33(6):521-7. Epub 2007 Jul 19. Review.

PMID:
17658220
4.

Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.

Choong PF, Nadesapillai AP.

Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S46-58. Review.

PMID:
14600592
6.

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.

Magdolen V, Krüger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U, Schmitt M.

Recent Results Cancer Res. 2003;162:43-63. Review.

PMID:
12790320
7.

Urokinase-type plasminogen activator system and breast cancer (Review).

Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K.

Oncol Rep. 2005 Jul;14(1):105-12. Review.

PMID:
15944776
8.

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.

Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V.

Curr Pharm Des. 2003;9(19):1529-43. Review.

PMID:
12871066
9.
10.

[The clinical prospects for the study of the plasminogen activation system in breast cancer].

Gershteĭn ES, Kushlinskiĭ NE.

Vestn Ross Akad Med Nauk. 1999;(8):58-61. Review. Russian.

PMID:
10487126
11.

Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.

Pakneshan P, Szyf M, Rabbani SA.

Curr Cancer Drug Targets. 2005 Nov;5(7):471-88. Review.

PMID:
16305345
12.

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

Sidenius N, Blasi F.

Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):205-22. Review.

PMID:
12784997
13.

The urokinase-system--role of cell proliferation and apoptosis.

Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N.

Histol Histopathol. 2008 Feb;23(2):227-36. Review.

PMID:
17999379
14.

Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.

Mazar AP.

Clin Cancer Res. 2008 Sep 15;14(18):5649-55. doi: 10.1158/1078-0432.CCR-07-4863. Review.

15.
16.

The urokinase plasminogen activator system: role in malignancy.

Duffy MJ.

Curr Pharm Des. 2004;10(1):39-49. Review.

PMID:
14754404
17.

The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.

Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV, Iaccarino I, Stoppelli MP.

Thromb Haemost. 2005 Feb;93(2):205-11. Review.

PMID:
15711734
18.

uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.

Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G.

Curr Drug Targets. 2011 Nov;12(12):1744-60. Review.

PMID:
21707477
19.

Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.

Mohanam S, Gladson CL, Rao CN, Rao JS.

Front Biosci. 1999 Feb 15;4:D178-87. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk